OPEN ACCESS Freely available online

Mycobacterial Diseases

ISSN: 2161-1068

Perspective

Tuberculosis Susceptibility and Treatment Response in Microbiome's

Chong Wang*

Department of Medical Bacteriology, Munich Medical Research School, Ludwig Maximilian University of Munich (LMU), Munich, Germany

DESCRIPTION

Tuberculosis (TB) is one of the oldest and deadliest infectious diseases in human history, caused by the bacterium *Mycobacterium tuberculosis* (*M. tuberculosis*). While much progress has been made in TB research and treatment, the factors influencing TB susceptibility and treatment outcomes remain complex and multifaceted. In recent years, there has been a growing interest in understanding the role of the human microbiome in TB. The human microbiome, a diverse community of microorganisms living within our bodies, is increasingly recognized for its impact on health and disease. This article explores the emerging field of microbiome research in TB, interesting on its potential to transform our understanding of TB susceptibility, disease progression, and treatment response.

The human microbiome

The human microbiome consists of trillions of microorganisms, including bacteria, viruses, fungi, and archaea, that inhabit various parts of our body, such as the skin, mouth, gut, and respiratory tract. These microorganisms form a complex and dynamic ecosystem that plays an important role in human health. The microbiome is involved in digestion, metabolism, immune function, and protection against pathogens. Disturbances in the balance of this microbial community, known as dysbiosis, have been linked to various diseases, including inflammatory bowel disease, diabetes, and autoimmune disorders.

The respiratory microbiome and TB

The respiratory tract, including the upper airways and lungs, harbors a unique and dynamic microbiome. Research into the respiratory microbiome's role in TB has revealed intriguing insights:

Dysbiosis and TB susceptibility: Changes in the composition and diversity of the respiratory microbiome have been associated with an increased risk of TB. Imbalances in the microbiome can compromise the respiratory tract's ability to turn away *M. tuberculosis*, potentially making individuals more susceptible to infection.

Immune crosstalk: The respiratory microbiome interacts with the host immune system. Some resident bacteria play a role in educating and priming immune responses. Dysbiosis may disrupt these interactions, affecting the immune system's ability to control TB infection.

Treatment response: Emerging evidence suggests that the respiratory microbiome can influence TB treatment outcomes. Dysbiosis during treatment may affect drug metabolism and immune responses, influencing the efficacy of anti-TB medications.

Lung health: Maintaining a healthy respiratory microbiome is essential for lung health. Dysbiosis can lead to chronic lung conditions, making individuals more susceptible to TB or worsening existing TB-related lung damage.

Mechanisms of microbiome influence in TB

Several mechanisms underlie the microbiome's influence on TB:

Immune modulation: The microbiome can influence the immune system's response to TB. Certain resident bacteria stimulate immune cells and help shape the appropriate response to *M. tuberculosis*. Dysbiosis may lead to immune dysfunction, hindering the body's ability to control the infection.

Competition for resources: Resident microbiota can compete with *M. tuberculosis* for essential nutrients and resources, potentially limiting the bacterium's growth and spread. Dysbiosis may disrupt this competition, providing *M. tuberculosis* with a growth advantage.

Metabolism and drug interactions: The microbiome can metabolize drugs, affecting their efficacy and toxicity. Dysbiosis may alter drug metabolism, influencing the treatment response and potentially leading to drug resistance.

Mucosal integrity: A healthy microbiome contributes to the maintenance of mucosal integrity in the respiratory tract. Dysbiosis can compromise the lung's barrier function, allowing *M. tuberculosis* to invade more easily.

Correspondence to: Chong Wang, Department of Medical Bacteriology, Munich Medical Research School, Ludwig Maximilian University of Munich (LMU), Munich, Germany, E-mail: Chongwang69@163.com

Received: 04-Jul-2023, Manuscript No. MDTL-23-27136; **Editor assigned:** 06-Jul-2023, Pre QC No. MDTL-23-27136 (PQ); **Reviewed:** 20-Jul-2023, QC No. MDTL-23-27136; **Revised:** 27-Jul-2023, Manuscript No. MDTL-23-27136 (R); **Published:** 03-Aug-2023, DOI: 10.35248/2161-1068.23.13.372.

Citation: Wang C (2023) Tuberculosis Susceptibility and Treatment Response in Microbiome's. Mycobact Dis.13:372.

Clinical implications

Understanding the role of the microbiome in TB susceptibility and treatment response has important clinical implications:

Personalized treatment: Making TB treatment regimens based on an individual's microbiome profile may improve treatment outcomes. Identifying microbial factors that influence drug metabolism can guide personalized therapy.

Adjunct therapies: Probiotics or microbiome-targeted therapies may be used as adjunct treatments to modulate the microbiome and enhance TB treatment responses.

Disease prevention: Strategies to maintain a healthy respiratory microbiome, such as promoting good lung health and reducing dysbiosis risk factors, could contribute to TB prevention efforts.

Early diagnosis: Microbiome profiling may serve as a diagnostic tool for identifying individuals at higher risk of TB or those more likely to experience treatment challenges.

Challenges and future directions

The study of the microbiome in TB is still in its infancy, and several challenges must be addressed:

Microbiome variability: The respiratory microbiome can vary widely among individuals, making it challenging to establish definitive cause-and-effect relationships with TB susceptibility or treatment response.

Causality *vs.* association: Establishing causality between microbiome alterations and TB outcomes is complex. Further research is needed to elucidate the precise mechanisms and causal links.

Standardization: Standardized methods for microbiome analysis and data interpretation are essential to ensure consistency and comparability across studies.

Ethical considerations: The collection and use of microbiome data raise ethical considerations related to privacy and informed consent.

CONCLUSION

The role of the human microbiome in TB susceptibility and treatment response is a expand field with the potential to transform our understanding of this ancient disease. While many questions remain, the emerging evidence highlights the microbiome's intricate influence on TB and the opportunities it presents for personalized medicine and improved TB control strategies. As research in this area advances, it may unlock place for preventing and treating TB, moving us near to aim eradicating this global health threat.